Pathos AI announced two separate licensing and co-development agreements with Alphamab Oncology and AstraZeneca, expanding its clinical-stage pipeline of targeted cancer therapies using its proprietary platform, Foundry.
Under the agreement with Alphamab, Pathos receives exclusive rights outside Greater China to develop and commercialize JSKN016, a potentially first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC). Alphamab will receive $125 million upfront, up to $2.09 billion in potential development and commercial milestones, plus tiered royalties on net sales. Pathos will fund and lead global development for JSKN016, which is currently in Phase III evaluation for triple-negative breast cancer (TNBC) in China, alongside early-stage studies in other solid tumors.
Separately, Pathos entered into a co-development agreement with AstraZeneca for AZD4241, a preclinical oral proteolysis-targeting chimera (PROTAC) designed to degrade both wild-type and mutated estrogen receptors in ER+/HER2- breast cancer. Pathos will lead early clinical execution, using Foundry to optimize trial design and patient selection.
Both assets were evaluated and prioritized using Foundry, Pathos’ AI-native platform designed to analyze biological and clinical data at scale to identify clinical candidates and match them to responder populations.
“The bottleneck in oncology is not finding molecules; it is proving they work in the right patients,” said Iker Huerga, CEO of Pathos AI. “Foundry’s role is to design precision clinical trials that match these therapies to the patients whose biology demands them.”
These agreements add to Pathos’ pipeline, which includes clinical programs in prostate cancer, multiple myeloma, non-small cell lung cancer, and brain tumors.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
